David Peralta - Chief Executive Officer
Mr. Peralta has served as Chief Executive Officer of NanoBio since July 2012. He joined NanoBio in February 2006, and served as Chief Operating and Financial Officer from 2006 through June 2012. During such time, Mr. Peralta was directly responsible for all of the company's business development, fundraising and finance-related activities, in addition to managing the company’s day-to-day operations. Prior to joining NanoBio, Mr. Peralta most recently served as Vice President and Chief Financial Officer for Arbortext, Inc., a venture-backed enterprise software company. While at Arbortext, Mr. Peralta played a key role in transforming the company to a high-growth software business, which ultimately led to Arbortext being acquired in 2005 for $195 million in cash. Before joining Arbortext, Peralta served for six years as the Chief Financial Officer of Mechanical Dynamics, Inc. (NASDAQ: MDII), a publicly-held software company. Mr. Peralta directed all finance and investor relations activities at Mechanical Dynamics during the company's initial public offering in 1996, and up through the sale of the company in 2002. Mr. Peralta is a Certified Public Accountant in the State of Michigan.
Ali I. Fattom, PhD - Sr. Vice President Vaccine Research and Development
Dr. Fattom joined NanoBio in November 2010 with 25 years of experience in vaccine research and development. He initiated his career as a vaccinologist at The National Institutes of Health, where he helped develop several vaccines including Pneumococcus conjugate vaccine and headed the effort for developing a S. aureus vaccine. He later joined Univax Biologics to pursue the development of conjugate vaccines against bacterial infections including Staphylococci. Following the merger between Univax and North American Biologics to form Nabi Biopharmaceuticals, Dr. Fattom assumed responsibility for other research activities and served as Vice President of Research from 2003 to 2010. He earned a B. S. from The Hebrew University of Jerusalem, a M.S. in Microbiology from Tel-Aviv University, and a Ph.D. in Microbial Ecology from the Hebrew University of Jerusalem. From 1983-1986 he held an assistant professorship at Bir-Zeit University, West Bank. Dr. Fattom is author of over 50 peer reviewed publications, and holds more than 10 patents.
Stephen (Steve) Gracon, DVM– Vice President of Regulatory Affairs
Steve Gracon, joins NanoBio with 30 years experience in the pharmaceutical industry at Parke-Davis, Pfizer, Amgen and Baxter. Steve brings a diversity to NanoBio having spent 8 years in preclinical pathology and experimental toxicology, more than a decade in clinical research during which he lead the development of the tacrine (Cognex) the first drug approved for the treatment of Alzheimer’s disease before moving to Regulatory Affairs gaining both International and US Regulatory experience. Steve comes to NanoBio with a unique combination of experiences with small and large molecules and plasma derived products. He returns to Ann Arbor with great enthusiasm for the scientific community and the entrepreneurial spirit offered within the team at NanoBio.
Tarek Hamouda, MD, PhD, MBA, Sr. Director of Vaccine Research
Dr. Hamouda has over 16 years of experience in antimicrobial drug and vaccine development and over 12 years of experience at NanoBio where he directed pre-clinical research, contributed to phase 1, 2 and 3 drug development and led phase 1 clinical vaccine development. Dr. Hamouda received his MD and his PhD in microbiology and immunology from the Faculty of Medicine, Cairo University. He had his post-doctoral work at Wayne State University focused on the development of a treatment for HIV using Herpes simplex virus virion host shut-off gene. In 1997, he joined Dr. James Baker’s Laboratory at the University of Michigan where he directed the development of novel broad-spectrum antimicrobial nanoemulsions and nanoemulsion vaccine adjuvants. His work at NanoBio supported the advancement of 4 products to clinical trials, the granting of 9 patents, the publication of 16 peer reviewed articles. Currently he is focused on NanoBio’s development program for adjuvanted RSV, HSV-2, anthrax and influenza vaccines. He received his MBA degree from Michigan State University in December 2007.
Vira Bitko, PhD - Director of Virology
Dr. Bitko has over 20 years of experience in virology, biochemistry and molecular biology including development of non-adjuvanted and adjuvanted viral vaccines and anti-virals. She joined NanoBio in July 2011 after having served as a Principal Virologist at Meridian Life Science where she was involved in development of viral vaccines, recombinant protein biotherapeutic production, analytical test method development and validation. Dr. Bitko gained extensive experience in molecular virology and innate immune responses to viral infections as a faculty member at the Department of Biochemistry and Molecular Biology at the University of South Alabama, where she studied Respiratory Syncytial Virus, metapneumovirus and Human Parainfluenza Virus and developed and advanced RNA interference method for the treatment of RSV infection. Dr. Bitko holds M.S. and PhD degrees in Biochemistry.
Susan Ciotti, PhD - Director of Formulations
Dr. Ciotti directs the development of novel nanoemulsion systems for the treatment of various dermatological conditions and vaccines for intranasal and intramuscular administration. She is also responsible for developing novel formulations to support the nanoemulsion platform, process optimization and scale-up activities for those formulations.
Before joining with NanoBio, she was an Associate Research Fellow at Pfizer Global R&D in Ann Arbor. She led all the formulation efforts for the Dermatology programs. Prior to joining Pfizer, she was a Principal Scientist in the Topical Formulations & Drug Delivery Technology Resource Center at Johnson & Johnson.
Dr. Ciotti is currently an Adjunct Associate Professor of Pharmaceutical Sciences at the University of Michigan, College of Pharmacy in Ann Arbor, Michigan. She lectures on Advanced Drug Delivery Systems and Nanotechnology. She is also a reviewer for several journals, served as an invited speaker at several international conferences and as a guest speaker at the FDA in the field of novel drug delivery technologies and nanotechnology.
Maen Qadan, PhD, MBA - Director of Vaccine Development & Manufacturing
Dr. Qadan has more than 17 years of experience in protein expression and purification. He has worked in the biopharmaceutical industry for close to 10 years in process development, clinical, and commercial biologics manufacturing. At NanoBio, he is responsible for process development, scale up, and manufacturing of vaccines. Prior to his current role, Dr. Qadan worked as a manager in the Manufacturing Sciences and Technology department at Bristol-Myers Squibb. He supported the manufacturing and life-cycle management of several commercial and late stage development programs. Before joining BMS, Dr. Qadan worked as a senior scientist at Nabi Biopharmaceuticals where he led the process development, scale up, and manufacturing of three S. aureus vaccine antigens that were acquired by GlaxoSmithKline. Earlier in his career, he worked as a protein chemist at Inhibitex, a BMS subsidiary. Dr. Qadan trained as a research fellow at the Harvard Medical School where he studied anthrax toxin. He holds a Ph.D. in Microbiology from the University of Oklahoma, an MBA from Cornell University, and a BS in Biology from the University of Jordan.
Douglas M. Smith, PhD - Director of Immunology
Dr. Smith joined NanoBio in November 2013 with over 20 years of experience in immunology including cellular and antibody-based immunotherapies and vaccines against cancer and infectious diseases. He received a B.Sc. degree in Microbiology and Immunology from McGill University and a Ph.D. in Immunology from The University of Chicago. As Principal Scientist and Immunology Program Leader at Aastrom Biosciences, Inc., he established and directed programs for clinical-scale production of dendritic cell vaccines, T-lymphocyte-based adoptive immunotherapies, and immunologic characterization of an adult stem cell product for human tissue repair. Dr. Smith gained extensive experience in the development, characterization and evaluation of nanoemulsions as novel adjuvants for induction of mucosal and systemic immunity as a faculty member of the Michigan Nanotechnology Institute for Medicine and Biological Sciences (2008-2013) at the University of Michigan. He is currently responsible for development of NanoVax-PanFlu, a nanoemulsion-adjuvanted vaccine against H5N1 pandemic influenza, and other mucosal vaccines to prevent respiratory or sexually-transmitted diseases such as herpes simplex virus and HIV/AIDS.